Non-cystic fibrosis bronchiectasis: inhaled tobramycin

Non-cystic fibrosis bronchiectasis: inhaled tobramycin – evidence summary (ES12)
Information type: Evidence summaries
Source: National Institute for Health and Care Excellence
Specialities: Infection and infectious diseases | Respiratory disorders
Summary
This evidence summary includes data from 3 RCTs that investigated the efficacy of nebulised tobramycin, 300 mg twice daily vs placebo for infective exacerbations caused by P aeruginosa in people with non-cystic fibrosis bronchiectasis.
UKMi comment
Use of inhaled tobramycin for treating infective exacerbations caused by Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis is off-label.
Related links:

Non-cystic fibrosis bronchiectasis: inhaled tobramycin – evidence summary (ES12)